Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]
Sponsor: The University of Texas Health Science Center at San Antonio
Summary
The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug to prevent transplant rejection, increases the lifespan and healthspan of mice and ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in laboratory animals. Investigators are conducting a translational trial to test whether rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95). Substudy E will evaluate the Rapamycin and Cardiac Function.
Official title: Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Functional Consequences ((Substudy E - RAPA cMRI With LGE)
Key Details
Gender
All
Age Range
70 Years - 95 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2022-02-01
Completion Date
2026-10-16
Last Updated
2026-09-23
Healthy Volunteers
Yes
Conditions
Interventions
rapamycin
Taken orally 1mg daily for 8 weeks
Locations (2)
Audie L. Murphy Memorial Veterans Hospital
San Antonio, Texas, United States
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States